News about Global Pharma

Cipher Pharmaceuticals Secures pCPA Agreement to Expand Public Access to Epuris Across Canada

Cipher Pharmaceuticals has completed negotiations with the pan-Canadian Pharmaceutical Alliance, securing a Letter of Intent for Epuris (isotretinoin). The agreement represents a significant step toward expanding public drug plan coverage and improving patient access to severe acne treatment across Canada.

Global Pharma | 09/07/2026 | By News Bureau |  113

EMA Fast-Tracks Review of New Metastatic Pancreatic Cancer Drug

The European Medicines Agency (EMA) has initiated a phased review of a new medicine for metastatic pancreatic cancer, accelerating its assessment to address a significant unmet medical need.

Global Pharma | 09/07/2026 | By News Bureau

Insilico Medicine Advances AI-Discovered IPF Drug Rentosertib into Phase III Clinical Trial

Rentosertib, formerly known as ISM001-055/INS018_055, is a potentially first-in-class oral small-molecule inhibitor targeting TNIK (TRAF2 and NCK-interacting kinase) for the treatment of IPF, a progressive and irreversible lung disease with limited treatment options.

Global Pharma | 08/07/2026 | By Abha |  289

Vertex to Acquire Crinetics Pharmaceuticals for USD 10 Billion

Under the terms of the agreement, Vertex will acquire all outstanding shares of Crinetics for USD 85 per share in cash, representing a net transaction value of approximately USD 8.8 billion after accounting for estimated cash acquired.

Global Pharma | 08/07/2026 | By Abha |  162

Ascletis Submits 2 IND Applications to the US FDA for the Treatment of Obesity

Ascletis has submitted two IND applications to the US FDA for once-monthly obesity therapies, including ASC36_35, a first-in-class triple-target candidate acting on amylin receptor, GLP-1R and GIPR.

Global Pharma | 06/07/2026 | By Akanki |  124

Newron Provides Update Following Type A Meeting with the US FDA

Newron has provided an update following its Type A meeting with the US Food and Drug Administration (FDA), outlining the steps required to resume US enrollment in the phase 3 ENIGMA-TRS 2 schizophrenia study.

Global Pharma | 04/07/2026 | By News Bureau |  169

Lilly Completes Acquisition of Centessa to Advance Sleep Disorder Therapies

Lilly expands its neuroscience portfolio with the acquisition of Centessa Pharmaceuticals to accelerate treatments for narcolepsy and related sleep disorders.

Global Pharma | 26/06/2026 | By News Bureau |  118

Biocon Expands Diabetes Care in Malaysia as Duopharma Wins Insulin Tenders

Biocon strengthens diabetes care in Malaysia as Duopharma Biotech secures insulin tenders worth over MYR 225 million for human insulin, insulin glargine, and insulin aspart.

Global Pharma | 26/06/2026 | By News Bureau |  126

Aurobindo Pharma USA Receives FTC Approval to Acquire Lannett Company

Aurobindo Pharma USA receives FTC approval to acquire Lannett Company in a USD 250 million deal. The transaction is expected to close before the end of June 2026.

Global Pharma | 22/06/2026 | By News Bureau

Biogen to Acquire RayThera in Deal Worth Up to USD 1 Billion to Strengthen Immunology Pipeline

Biogen has agreed to acquire immunology-focused biotech firm RayThera in a deal worth up to USD 1 billion, gaining a portfolio of anti-inflammatory drug candidates and strengthening its pipeline for immune-mediated diseases.

Global Pharma | 20/06/2026 | By News Bureau |  151